-
-
-
-
-
-
-
Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™
-
-
-
-
-
-
-
Sesen Bio (SESN) Reports Productive Type A Meeting with the FFA
-
-
-
-
-
-
-
Sesen Bio Announces Partnership with Eczacibasi Pharmaceuticals Marketing (EIP) for the Commercialization of Vicineum™ in Turkey
-
-
-
-
-
-
-
Sesen Bio (SESN) Announces Productive Late-Cycle Meeting with the FDA for Vicineum
-
-
-
-
-
-
-
Dr. Thomas Cannell, President and CEO of Sesen Bio, to Participate in Fireside Chat at the 2021 Jefferies Virtual Healthcare Conference
-
-
-
-
-
-
-
Sesen Bio (SESN) Announces ISS and Glass Lewis Recommend “FOR” Proposal to Increase Authorized Shares
-
-
-
-
-
-
-
Sesen Bio Submits Marketing Authorization Application to the European Medicines Agency for Vicineum™
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

